Immunoprecise Antibodies Ltd (IPA)

$0.63

+0.08

(+15.21%)▲

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $0.55
    $0.63
    $0.63
    downward going graph

    12.7%

    Downside

    Day's Volatility :12.7%

    Upside

    0.0%

    downward going graph
  • $0.50
    $2.60
    $0.63
    downward going graph

    21.43%

    Downside

    52 Weeks Volatility :80.96%

    Upside

    75.77%

    downward going graph

Returns

PeriodImmunoprecise Antibodies LtdIndex (Russel 2000)
3 Months
-45.75%
0.0%
6 Months
-62.33%
0.0%
1 Year
-66.72%
0.0%
3 Years
-90.73%
-20.6%

Highlights

Market Capitalization
16.3M
Book Value
$1.2
Earnings Per Share (EPS)
-0.79
Wall Street Target Price
5.99
Profit Margin
-115.22%
Operating Margin TTM
-86.23%
Return On Assets TTM
-13.45%
Return On Equity TTM
-64.04%
Revenue TTM
24.1M
Revenue Per Share TTM
0.92
Quarterly Revenue Growth YOY
-7.5%
Gross Profit TTM
11.6M
EBITDA
-11.5M
Diluted Eps TTM
-0.79
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.34
EPS Estimate Next Year
-0.25
EPS Estimate Current Quarter
-0.08
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 6 Wall street analysts offering stock ratings for Immunoprecise Antibodies Ltd(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
5
5
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 850.79%

Current $0.63
Target $5.99

Company Financials

FY19Y/Y Change
Revenue
8.2M
↑ 100.8%
Net Income
-5.7M
↑ 47.31%
Net Profit Margin
-69.72%
↑ 25.31%
FY20Y/Y Change
Revenue
10.0M
↑ 28.66%
Net Income
-3.5M
↓ 35.05%
Net Profit Margin
-35.19%
↑ 34.53%
FY21Y/Y Change
Revenue
14.3M
↑ 27.42%
Net Income
-5.9M
↑ 48.36%
Net Profit Margin
-40.98%
↓ 5.79%
FY22Y/Y Change
Revenue
15.3M
↑ 8.11%
Net Income
-13.2M
↑ 127.64%
Net Profit Margin
-86.29%
↓ 45.31%
FY23Y/Y Change
Revenue
15.3M
↑ 6.72%
Net Income
-19.7M
↑ 58.96%
Net Profit Margin
-128.53%
↓ 42.24%
FY24Y/Y Change
Revenue
17.9M
↑ 18.65%
Net Income
-19.9M
↑ 2.32%
Net Profit Margin
-110.85%
↑ 17.68%
Q2 FY23Q/Q Change
Revenue
4.2M
↑ 8.7%
Net Income
-3.8M
↑ 9.15%
Net Profit Margin
-91.25%
↓ 0.38%
Q3 FY23Q/Q Change
Revenue
3.5M
↓ 16.58%
Net Income
-7.1M
↑ 82.9%
Net Profit Margin
-200.06%
↓ 108.81%
Q4 FY23Q/Q Change
Revenue
4.5M
↑ 31.16%
Net Income
-1.9M
↓ 72.05%
Net Profit Margin
-42.63%
↑ 157.43%
Q1 FY24Q/Q Change
Revenue
4.6M
↑ 0.0%
Net Income
-2.0M
↑ 0.0%
Net Profit Margin
-42.63%
↑ 0.0%
Q2 FY24Q/Q Change
Revenue
4.7M
↑ 5.02%
Net Income
-13.2M
↑ 588.22%
Net Profit Margin
-279.38%
↓ 236.75%
Q3 FY24Q/Q Change
Revenue
3.8M
↓ 18.52%
Net Income
-2.9M
↓ 77.84%
Net Profit Margin
-75.98%
↑ 203.4%
FY19Y/Y Change
Total Assets
21.2M
↑ 15.34%
Total Liabilities
7.7M
↓ 13.44%
FY20Y/Y Change
Total Assets
19.4M
↓ 3.82%
Total Liabilities
8.7M
↑ 18.49%
FY21Y/Y Change
Total Assets
53.6M
↑ 145.6%
Total Liabilities
8.0M
↓ 17.59%
FY22Y/Y Change
Total Assets
74.1M
↑ 39.63%
Total Liabilities
14.4M
↑ 81.45%
FY23Y/Y Change
Total Assets
57.7M
↓ 16.77%
Total Liabilities
14.8M
↑ 9.89%
FY24Y/Y Change
Total Assets
43.9M
↓ 22.91%
Total Liabilities
19.1M
↑ 30.27%
Q2 FY23Q/Q Change
Total Assets
57.7M
↓ 5.61%
Total Liabilities
14.8M
↓ 6.31%
Q3 FY23Q/Q Change
Total Assets
60.5M
↑ 2.74%
Total Liabilities
10.4M
↓ 31.52%
Q4 FY23Q/Q Change
Total Assets
55.2M
↓ 5.42%
Total Liabilities
17.2M
↑ 72.05%
Q1 FY24Q/Q Change
Total Assets
56.4M
↑ 0.0%
Total Liabilities
17.6M
↑ 0.0%
Q2 FY24Q/Q Change
Total Assets
43.9M
↓ 20.66%
Total Liabilities
19.1M
↑ 10.57%
Q3 FY24Q/Q Change
Total Assets
43.2M
↓ 1.15%
Total Liabilities
19.3M
↑ 1.45%
FY19Y/Y Change
Operating Cash Flow
-2.4M
↓ 6.14%
Investing Cash Flow
-1.6M
↓ 69.3%
Financing Cash Flow
7.0M
↓ 4.59%
FY20Y/Y Change
Operating Cash Flow
-990.1K
↓ 56.61%
Investing Cash Flow
-1.1M
↓ 28.1%
Financing Cash Flow
124.3K
↓ 98.13%
FY21Y/Y Change
Operating Cash Flow
-480.0K
↓ 56.87%
Investing Cash Flow
-2.0M
↑ 55.14%
Financing Cash Flow
34.7M
↑ 24730.42%
FY22Y/Y Change
Operating Cash Flow
-7.9M
↑ 1553.5%
Investing Cash Flow
-4.1M
↑ 112.05%
Financing Cash Flow
2.3M
↓ 93.35%
FY23Y/Y Change
Operating Cash Flow
-14.7M
↑ 99.91%
Investing Cash Flow
-1.5M
↓ 62.23%
Financing Cash Flow
-460.7K
↓ 121.54%
Q2 FY23Q/Q Change
Operating Cash Flow
-1.7M
↓ 36.96%
Investing Cash Flow
-329.4K
↑ 96.46%
Financing Cash Flow
-282.6K
↑ 35.11%
Q3 FY23Q/Q Change
Operating Cash Flow
-7.8M
↑ 361.68%
Investing Cash Flow
-149.0K
↓ 55.63%
Financing Cash Flow
-115.0K
↓ 60.1%

Technicals Summary

Sell

Neutral

Buy

Immunoprecise Antibodies Ltd is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Immunoprecise Antibodies Ltd
Immunoprecise Antibodies Ltd
-19.07%
-62.33%
-66.72%
-90.73%
-96.6%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-11.82%
7.63%
22.08%
84.17%
257.49%
Novo Nordisk A/s
Novo Nordisk A/s
-12.08%
-8.57%
27.88%
136.23%
343.21%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
7.18%
75.52%
50.82%
35.89%
250.13%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.21%
11.53%
27.71%
156.23%
163.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Immunoprecise Antibodies Ltd
Immunoprecise Antibodies Ltd
NA
NA
NA
-0.34
-0.64
-0.13
NA
1.2
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.55
27.55
1.42
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.7
38.7
1.75
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.55
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Immunoprecise Antibodies Ltd
Immunoprecise Antibodies Ltd
Buy
$16.3M
-96.6%
NA
-115.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.7B
257.49%
27.55
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$518.0B
343.21%
38.7
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.9B
250.13%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$119.3B
163.62%
32.84
-4.74%

Insights on Immunoprecise Antibodies Ltd

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 6.45M → 5.26M (in $), with an average decrease of 18.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -18.04M → -3.99M (in $), with an average increase of 351.2% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 50.8% return, outperforming this stock by 117.5%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 35.9% return, outperforming this stock by 126.6%

Institutional Holdings

  • Ingalls & Snyder LLC

    4.74%

  • Renaissance Technologies Corp

    0.23%

  • BMO Capital Markets Corp.

    0.20%

  • Bank of Montreal

    0.20%

  • Northern Trust Corp

    0.19%

  • CIBC World Markets Inc.

    0.15%

Company Information

immunoprecise antibodies is a highly specialized customer focused life sciences company that provides custom antibody development and immunology services from its headquarters in beautiful victoria, bc, canada. our dedication to advancing antibody development has resulted in cutting-edge immunological innovations such as single-step cloning, rapid prime immunization strategies, and recombinant monoclonal technology. we pride ourselves on our high customer satisfaction and our clients have grown accustomed to receiving thorough and professional service. we customize your project to generate antibodies that meet your specific needs. over our 20+ year history, we have gained the trust of a diverse group of customers that include research agencies, universities, biotechnology and pharmaceutical companies of all sizes from around the globe. immunoprecise is pleased to announce its newest line of services, immunoprotect™. with immunoprotect™, the dna sequence of your mab is determined and ca

Organization
Immunoprecise Antibodies Ltd
Employees
72
CEO
Dr. Jennifer Lynne Bath Ph.D.
Industry
Miscellaneous

Discover More

FAQs